CTIX sure looks interesting. Three different cancer treatment trials recently announced with same product "Kevetrin". Funding provided by Dana Farber Cancer Center, Beth Israel Hospital/Pfizer and today a top 10 European Hospital/Major European Pharma. It's rare to see a small market cap biotech get fully paid clinical trials from 3 different respected Institutions aiming at three different cancer targets. Early clinical trials indicate crucial P53 enhancement is enabled by Kevetrin and lack of P53 is thought to be the key ingredient to survival in 50% of cancer cases. Dana Farber trials target cancer patients with less than 6 months to live.
No dilution to fund 3 different cancer trials is pretty impressive for a penny stock. They also have just been approved for a phase 2/3 Psoriasis treatment with another product.
Company link appears to be down right now. Possibly more info coming for the R & R conference tomorrow where managemnt will present.
News 
Market Data 
Discover 
